Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest...
Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside...
Merck KGaA has announced a €70 million expansion of its ADC manufacturing capacity at its Centre of Excellence for Bioconjugation in St. Louis, Missouri, USA. The...
Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...
Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...
26.09.2017
- ADC Biotechnology (ADC Bio) has secured investment for the construction of an $11 million bioconjugation facility at its new site in Deeside, North Wales, UK. A substantial part of...
14.09.2010
- What do you consider to be the biggest trends in custom manufacturing? J. Decker-Conradi (Bayer Healthcare): We at Bayer HealthCare (BHC) look for suppliers which are reliable and...
14.09.2010
- The name of the game is focusing on core competencies - and this is something custom manufacturers have been able to benefit from over the last several years. This trend has set...
